NEUROCRINE BIOSCIENCES, INC. (NBIX): what the price assumes

In the published model solve dated 2026-Q2, anchored at $161.48, NEUROCRINE BIOSCIENCES, INC. (NBIX) is priced for +10.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/NBIX

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.4% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.2pp.

How unusual the bet is: within-range

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.6%); the inversion above states its own rate.

Per-Model Detail (n=18)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Neurocrine Biosciences is a profitable, net-cash biotech built around INGREZZA, its tardive dyskinesia drug, which is about 88% of revenue, with the newer CRENESSITY adding roughly 11%. Trailing operating margin is about 25%, and the most recent quarter put net product sales above $800 million, up 44% year over year.

At $158.30 (June 27, 2026) the price pays about 26x company-wide operating income, which implies operating growth near 18% per year for five years. The static valuation families call the stock richly valued; only the forward growth method reaches the price, so the quote is a bet on durable compounding rather than a cheap multiple.

The balance sheet is pristine: about $1.3 billion of cash and no debt. That cash funds a pipeline meant to reduce the heavy reliance on a single product, which is both the central risk and the thing the company is actively working to fix.

Bull Case

The counterintuitive finding here is that the valuation methods call Neurocrine richly valued even though it is one of the cleaner profiles in biotech: a 25% operating margin, $1.3 billion of net cash, no debt, and a top line growing 44% year over year. The asset and earnings-power frames say expensive, yet the business is throwing off real cash and accelerating, which means the methods are penalizing it for the durability question rather than for any weakness in the numbers themselves. That mismatch is the bull's opening, because the thing the static frames cannot price, durable compounding from a drug with growing demand, is exactly what the recent results show.

INGREZZA is the engine and it is still growing the right way. The most recent quarter put INGREZZA sales at $657 million, up about 20% year over year, and management attributed the gain to double-digit volume growth and record new-patient additions rather than price or inventory, the highest-quality kind of growth a single product can show. Full-year INGREZZA guidance was reaffirmed at $2.7 billion to $2.8 billion. A franchise that keeps adding patients years into its life is not a fading asset, it is a deepening one, and it funds everything else the company is trying to build.

The second leg, CRENESSITY, is the part that changes the story. It contributed $153 million in the quarter, with the launch running ahead of expectations on steady new-patient starts, strong persistence, favorable reimbursement, and broad prescriber adoption. A second commercial product scaling quickly is what turns a one-drug company into a platform, and Neurocrine is using its net-cash position to push multiple Phase I and II programs in 2026 with key data readouts in 2027 (FY2025 10-K, accession 0000914475-26-000007 describes a pipeline spanning psychiatry, endocrinology, and related areas). The bull case is that the cash, the growing core drug, and the second launch together justify paying for compounding the static methods structurally cannot capture.

Bear Case

The structural truth a Neurocrine holder would rather not face is that this is still, today, essentially one drug. INGREZZA is about 88% of revenue, and even after a strong CRENESSITY launch the company's fortunes ride almost entirely on a single product's continued growth and eventual loss of exclusivity. The filing is direct that the company faces intense competition in developing and marketing its products, that competitors include large pharmaceutical companies, and that the development of generic equivalents could erode the market for its products (FY2025 10-K, accession 0000914475-26-000007). A 26x multiple and an implied 18% growth path assume that single-product engine keeps compounding for years, and concentration like this is precisely what the static methods are flagging when they call the stock expensive.

The second concern is the gap between the price and the methods. The asset, earnings-power, and peer-multiple frames all land below the current quote, and only the growth-DCF reaches it. That means the entire premium rests on the forward-growth assumption holding, and the base rate is sobering: only about 43% of comparable fast-growers sustained this pace for even five years. If INGREZZA volume growth decelerates or a competitive or pricing change appears before the pipeline delivers a third meaningful product, there is no cheaper method underneath to support the price.

The pipeline that is supposed to de-risk the concentration is also the source of binary risk. Key data readouts are guided for 2027, which means the next two years carry clinical-trial uncertainty where a failed readout removes a growth leg the price is partly counting on. The balance sheet, $1.3 billion of cash and no debt, gives the company room to absorb a setback without distress, but it does not protect the valuation. The bear case is not insolvency, it is that a single-product premium meets either a slowing core drug, a pipeline disappointment, or the first sign of the eventual exclusivity cliff, and the multiple compresses toward what the static methods already say the business is worth.

Valuation

At the current price the market is paying about 26x company-wide operating income, which implies operating growth of roughly 18% per year for five years. That solve runs at a cost of capital near 8.4% with 4% terminal growth over a five-year stage, and each point of cost of capital moves the implied growth rate by about 7.9 points, so the figure is sensitive to the discount assumption. Keep it approximate; it is a single inversion, not a forecast.

The family pattern is the key signal. The asset, earnings-power, and peer-multiple methods all read richly valued, and only the forward growth-DCF reaches the price. When three frames sit below the quote and one stretches to meet it, the price is a bet on durable compounding that the static methods structurally cannot capture, a moat-and-durability premium tied to INGREZZA's longevity and CRENESSITY's ramp. The reverse-DCF range on a whole-company basis centers below the current price with an acceptable reliability flag, so the gap is real, not a data artifact.

The grounding cuts both ways. On the bull side the near-term pace is within what the company has recently delivered, so the stretch is in how long it must persist rather than the rate. On the bear side, only about 43% of comparable fast-growers sustained that pace for five years, and the implied 18% leans heavily on the single dominant product. The $1.3 billion net-cash position is a genuine cushion that supports the pipeline spending, but it does not lower the durability bar the price has set. The valuation is reasonable if you believe the two-product franchise compounds; it is full if you weight the concentration the static methods are pricing.

Catalysts

The most recent print, Q1 2026 (reported early May 2026), was a record: net product sales above $800 million, up 44% year over year. INGREZZA contributed $657 million, up about 20%, driven by double-digit volume growth and record new-patient additions with no material inventory or one-off boost. CRENESSITY added $153 million, with management describing the launch as ahead of expectations on steady new-patient starts, strong persistence, favorable reimbursement, and broad prescriber adoption.

Forward, management reaffirmed full-year INGREZZA guidance of $2.7 billion to $2.8 billion and signaled it would update after the first half of 2026, so the mid-year guidance refresh is the next scheduled catalyst. CRENESSITY's continued ramp is the other near-term driver, since a second product scaling quickly is what most directly addresses the single-product concentration the bear case centers on.

The larger catalysts are clinical. The company plans multiple Phase I and II programs through 2026 with key data readouts in 2027, and those readouts are the events that could either add a third growth leg or remove one the price is partly counting on. The watch items are INGREZZA volume and competitive dynamics, CRENESSITY persistence and reimbursement, and pipeline progress toward the 2027 readouts. Sources: Neurocrine Q1 2026 results and earnings coverage (prnewswire.com; investing.com; stocktitan.net; marketbeat.com), May 2026.

Peer Cohorts (Per Segment, With Filing Citations)

Neurocrine Biosciences (neuroscience/endocrine/neuropsychiatry biopharma) (reported)

• ACAD (ACADIA PHARMACEUTICALS INC)
• FY2025 10-K: …strategy and are designed to enhance our competitive position, drive innovation, and meet the evolving needs of patients worldwide. The four core capabilities in which we are investing are: 1. Precision Medicine . We are focused on integrating strategies that address the variability in patients' responses to…
• FY2025 10-K: …competitors. Some of these competitors have products or are pursuing the development of pharmaceuticals that target the same diseases and conditions that our research and development programs target. For example, the use of NUPLAZID for the treatment of PDP competes with off-label use of various antipsychotic drugs,…
• HRMY (HARMONY BIOSCIENCES HOLDINGS, INC.)
• FY2025 10-K: Because a number of companies compete with us, many of which have greater resources than we do, and because we face rapid changes in science in our industry, we cannot be certain that our products will be accepted in the marketplace or capture market share. Competition from other biotechnology and pharmaceutical…
• FY2025 10-K: …trials in narcolepsy and IH in the fourth quarter of 2025. After receiving "Study May Proceed" letters from the FDA, the Phase 3 registrational study in narcolepsy, ONSTRIDE1, and the Phase 3 registrational study in IH, ONSTRIDE2, were initiated. We anticipate topline data from both studies in 2027 and a potential…
• ALKS (Alkermes plc.)
• FY2025 10-K: …among others, any of which could limit the potential success and growth prospects of products incorporating our NANOCRYSTAL technology. In addition, there are many competing technologies to our OCR technology, some of which are owned by large pharmaceutical companies with drug delivery divisions or other, smaller…
• FY2025 10-K: …in the marketplace, including generic competition, and the relative price of those products; the efficacy, safety and reliability of our products compared to competing or alternative products; product acceptance by, and preferences of, physicians, other healthcare providers and patients; our ability to comply with…
• CORT (CORCEPT THERAPEUTICS INC)
• FY2025 10-K: …biologics without generic or biosimilar competition. Orphan drugs are exempted from the Medicare drug price negotiation program provided that the only approved indications (or indications) is for one or more rare diseases or conditions for which the drug received orphan designation by FDA. Decreases in third-party…
• FY2025 10-K: …preliminary information as to its activity and/or efficacy. • Phase 2. The product candidate is administered to a limited patient population with a specified disease or condition to evaluate its preliminary efficacy, optimal dosages and to identify possible adverse events and safety risks. • Phase 3. The product…
• APLS (APELLIS PHARMACEUTICALS, INC.)
• FY2025 10-K: …order, the FDA restored the draft DAP guidance to its website with a statement that "information on this page may be modified and/or removed in the future subject to the terms of the court's order and implemented consistent with applicable law." Accordingly, in light of these ongoing actions, there is considerable…
• FY2025 10-K: …including: • the efficacy and safety of the product; • the potential advantages of the product compared to competitive therapies; 50 Table of Contents • the prevalence and severity of any side effects; • the clinical indications for which the product is approved; • whether the product is designated under physician…
• ALNY (ALNYLAM PHARMACEUTICALS, INC.)
• FY2025 10-K: …collaborators do or their technologies, including delivery technologies, are more effective, our and our collaborators' ability to successfully commercialize our products may be adversely affected. In addition to the competition we face from competing drugs in general, we and our collaborators also face competition…
• FY2025 10-K: …being marketed and/or under development at other companies. The competition we face can be grouped into three broad categories: • other companies working to develop RNAi and microRNA therapeutic products; • companies developing technology known as antisense, which, like RNAi, attempts to silence the activity of…
• FOLD (AMICUS THERAPEUTICS, INC.)
• FY2025 10-K: …ERA Inhibitor Phase 3 Vertex FSGS VX-147 Oral Inhibitor Phase 3 _____________________________ (1) Reflects commercial products and product candidates for which Investigational New Drug application ("IND") has been filed or are in clinical development. (2) In addition to the competitors listed in the table, we are…
• FY2025 10-K: …with BioMarin; • the success of competitive products or technologies; • regulatory actions with respect to our products or product candidates or our competitors' products or product candidates; • actual or anticipated changes in our growth rate relative to our competitors; • the outcome of any patent infringement or…
• TVTX (TRAVERE THERAPEUTICS, INC.)
• FY2025 10-K: …a Phase 3 study with BI 764198 (TRPC6 inhibitor) in adults and adolescent primary FSGS patients and FSGS patients with a TRPC6 gene mutation. Apellis Pharmaceuticals is conducting a dedicated sequential Phase 2/3 study in adults, followed by adolescents, with FSGS. Additionally, Vertex Pharmaceuticals is conducting…
• FY2025 10-K: …Various federal and state statutes and regulations also govern or influence analytical testing, manufacturing, safety evaluation, labeling, storage, inspection and record-keeping related to such products and their marketing. The process of obtaining these approvals and the subsequent compliance with appropriate…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.